Australia markets closed
  • ALL ORDS

    7,674.20
    +54.00 (+0.71%)
     
  • ASX 200

    7,362.00
    +50.30 (+0.69%)
     
  • AUD/USD

    0.7425
    +0.0004 (+0.06%)
     
  • OIL

    82.66
    +1.35 (+1.66%)
     
  • GOLD

    1,768.10
    -29.80 (-1.66%)
     
  • BTC-AUD

    83,015.12
    +2,347.87 (+2.91%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • AUD/EUR

    0.6396
    +0.0002 (+0.03%)
     
  • AUD/NZD

    1.0486
    -0.0054 (-0.52%)
     
  • NZX 50

    13,012.19
    -36.30 (-0.28%)
     
  • NASDAQ

    15,146.92
    +94.50 (+0.63%)
     
  • FTSE

    7,234.03
    +26.32 (+0.37%)
     
  • Dow Jones

    35,294.76
    +382.20 (+1.09%)
     
  • DAX

    15,587.36
    +124.64 (+0.81%)
     
  • Hang Seng

    25,330.96
    +368.37 (+1.48%)
     
  • NIKKEI 225

    29,068.63
    +517.70 (+1.81%)
     

Cardiovascular Drugs Market Size is Projected to Reach USD 63.96 Billion at CAGR to 3.8% by 2026

·4-min read

Cardiovascular Drugs Market Key Players Studied in this Report are Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, Merck & Co., Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd and other key market players.

Pune, India, Sept. 24, 2021 (GLOBE NEWSWIRE) -- According to the report, Cardiovascular Drugs Market size is projected to reach USD 63.96 billion at CAGR to 3.8% by 2026. The increasing demand for effective drugs and therapy is expected to aid the growth of the market. The rising R&D investment for innovative drugs and cardiovascular therapeutics will further accelerate the growth of the market. The launch of novel therapies by key players is likely to create growth opportunities for the market. For instance, Novartis AG and Blackstone’s Life Sciences announced the launch of Anthos Therapeutics for the development of cardiovascular drugs as there are large unmet needs for next-generation anti-thrombotic therapies in patients.

Moreover, in 2014, a study was conducted by the American Heart Association, cardiovascular disease accounted for more than 17.6 million deaths per year in 2016 and is likely to grow to more than 23.6 million by 2030.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cardiovascular-drugs-market-100379


The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease.

There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.


Click here to get the short-term and long-term impacts of COVID-19 on this Market. Please visit: https://www.fortunebusinessinsights.com/industry-reports/cardiovascular-drugs-market-100379


For instance, Bristol-Myers Squibb Company and Pfizer Inc. introduced a cardiovascular drug called Eliquis (apixaban), which now has the highest sales and is demonstrated to be superior in terms of risk reductions compared to other drugs in the market.

India based Natco Pharma announced the launch of the generic version of valsartan-sacubitril, a cardiovascular drug for the treatment of congestive heart failure. Novartis AG holds the patent in India for valsartan-sacubitril called Vymada. The launch of the new drug will create growth opportunities for the market in the foreseeable future.

Furthermore, increasing awareness regarding cardiovascular health and the surge in product launches will boost cardiovascular drugs market growth. The introduction of several advanced drugs addressing the diverse treatment needs of cardiovascular diseases will further bolster the growth of the market.


Quick Buy - Cardiovascular Drugs Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100379


Major key Players studied in report:

  • Bristol-Myers Squibb Company

  • Pfizer Inc.

  • Bayer AG

  • Janssen Pharmaceuticals, Inc.

  • AstraZeneca

  • Sanofi

  • Novartis AG

  • Merck & Co., Inc.

  • Gilead Sciences, Inc.

  • F. Hoffmann-La Roche Ltd

  • Others


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/cardiovascular-drugs-market-100379


Global Cardiovascular Drugs Market Segmentation:

By Drug Type:

  • Antihypertensive

  • Antihyperlipidemic

  • Anticoagulants

  • Antiplatelet Drugs

By Disease Indication:

  • Hypertension

  • Hyperlipidemia

  • Coronary Artery Disease

  • Arrhythmia, Others

By Distribution Channel:

  • Hospitals Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

By Geography

  • North America (U.S. and Canada)

  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, and Rest of Latin America)

  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/cardiovascular-drugs-market-100379


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting